Presbyopia Progression From the Age of 40 to 79 Years in Glaucoma Patients Treated With Prostaglandin F Receptor Agonists.

Purpose: The aim of this study was to compare the near add power of glaucoma patients and controls between the ages of 40 and 79 years.

Methods: This was a cross-sectional study of 2724 bilateral phakic participants aged between 40 and 79 years, which included 1615 controls and 1109 patients with primary open-angle glaucoma who were using prostaglandin F (FP) receptor agonists. Participants were classified into eight age groups: 40-44, 45-49, 50-54, 55-59, 60-64, 65-69, 70-74, and 75-79 years of age. We compared the near add power and other ocular parameters between glaucoma patients and controls by age group.

Results: There was a significant difference between glaucoma patients and controls and in spherical equivalent, intraocular pressure, cup/disc ratio, ganglion cell complex thickness, peripapillary retinal nerve fiber layer thickness, and use of dry eye eyedrops across all or many of the age groups studied. The near add power of glaucoma patients was comparable to controls of the immediately older age group until 65-69 years, indicating that the advancement of near add power of glaucoma patients was approximately five years earlier than in controls until that age range.

Conclusions: There was an earlier progression of presbyopia determined by near add power in glaucoma patients treated with FP receptor agonists compared with controls.

Translational Relevance: Between ages 40 and 79 years, glaucoma patients treated with prostaglandin F receptor agonists had higher near add power than controls. This knowledge could contribute to informing better management of glaucoma patients with presbyopia.